MiMedx Group Inc (MDXG) was Initiated by Piper Jaffray to “Overweight” and the brokerage firm has set the Price Target at $10. Piper Jaffray advised their Clients and Investors in a research report released on Mar 3, 2017.
Based on several research reports , Piper Jaffray Initiated MiMedx Group Inc on Mar 3, 2017 to “Overweight”, Price Target of the shares are set at $10.Piper Jaffray Initiated MiMedx Group Inc on Mar 3, 2017 to “Overweight”, Price Target of the shares are set at $10.UBS Initiated MiMedx Group Inc on Dec 12, 2016 to “Sell”, Price Target of the shares are set at $9.
On the company’s financial health, MiMedx Group Inc reported $0.05 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Feb 23, 2017. Analyst had a consensus of $0.07. The company had revenue of $69.90 million for the quarter, compared to analysts expectations of $70.71 million. The company’s revenue was up 34.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.07 EPS.
Several company insiders have filed Insider transactions , on Sep 8, 2016, William Charles Taylor (President and COO) sold 20,400 shares at $7.55 per share price. According to the SEC, on May 23, 2016, Parker H Petit (CEO) purchased 20,000 shares at $6.99 per share price. On Nov 16, 2015, Charles Robert Evans (director) purchased 10,000 shares at $7.84 per share price, according to the Form-4 filing with the securities and exchange commission.
MiMedx Group Inc opened for trading at $7.93 and hit $8.43 on the upside on Monday, eventually ending the session at $8.41, with a gain of 5.59% or 0.445 points. The heightened volatility saw the trading volume jump to 12,41,661 shares. Company has a market cap of $924 M.
MiMedx Group Inc. (MiMedx) is an integrated developer manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant which is referred as an allograft. MiMedx is the supplier of amniotic tissue having supplied over 350000 allografts for application in the Wound Care Surgical Sports Medicine Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.